Completed NA INTERVENTIONAL NCT00002453

A Compassionate Use Study of Tenofovir Disoproxil Fumarate as Treatment for HIV Infection

An Open-Label, Multicenter, Compassionate Access Study of the Safety of Tenofovir Disoproxil Fumarate Administered in Combination With Other Antiretroviral Agents for the Treatment of HIV-1 Infected Patients

Sponsor: Gilead Sciences

Conditions HIV Infections

Interventions Tenofovir disoproxil fumarate

Updated 5 times since 2017 Last updated: Jun 23, 2005 Started: Dec 31, 1999

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00002453, this NA trial focuses on HIV Infections and remains completed. Sponsored by Gilead Sciences, it has been updated 5 times since 1999, reflecting limited change activity. This study is part of the global effort to build evidence for infectious disease interventions.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed NA
Jul 2024 — Sep 2024 [monthly]

Completed NA
Jan 2021 — Jul 2024 [monthly]

Completed NA
Jun 2018 — Jan 2021 [monthly]

Completed NA
Jan 2017 — Jun 2018 [monthly]

Completed NA

First recorded

Dec 1999

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Gilead Sciences

Data source: NIH AIDS Clinical Trials Information Service

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Foster City, United States